Hepatitis C market forecast 2013−2022.
By Michael Haydock, Lead Analyst
24 April 2014
I am the Lead Analyst of the immunology and inflammation and infectious diseases and vaccines teams at Datamonitor Healt...
Read full bio
This webinar examines the sales trends of key marketed and pipeline brands within the hepatitis C market.
The hepatitis C market is on the cusp of a major transition from interferon-based treatments to all oral regimens, which display greatly improved efficacy, tolerability, and convenience.
This webinar will highlight how rival regimens being developed by Gilead, AbbVie, and Bristol-Myers Squibb will be positioned in the market. It will also examine how treatment paradigms for genotype 1/2/3 infections will be transformed over the forecast period.
Get the answers to these questions:
- How will the value of the market in the US, Japan, and five major EU markets change during 2013−2022?
- Which interferon-free regimens will be the most commercially successful and why?
- How will the arrival of interferon-free regimens affect treatment paradigms?
Posted in Infectious Diseases.